Abbott Laboratories (ABT) to Release Earnings on Wednesday

Abbott Laboratories (NYSE:ABT - Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, January 22nd. Analysts expect the company to announce earnings of $1.34 per share and revenue of $11,029,400.00 billion for the quarter.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.01. Abbott Laboratories had a net margin of 13.99% and a return on equity of 20.18%. The business had revenue of $10.64 billion during the quarter, compared to analyst estimates of $10.55 billion. During the same quarter in the previous year, the business earned $1.14 EPS. Abbott Laboratories's quarterly revenue was up 4.9% compared to the same quarter last year. On average, analysts expect Abbott Laboratories to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Abbott Laboratories Stock Performance

ABT traded down $2.06 on Wednesday, hitting $110.96. The company had a trading volume of 6,538,250 shares, compared to its average volume of 4,867,594. The stock has a market cap of $192.46 billion, a price-to-earnings ratio of 33.73, a price-to-earnings-growth ratio of 2.69 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.60 and a quick ratio of 1.14. The company's fifty day moving average price is $115.14 and its 200 day moving average price is $112.67. Abbott Laboratories has a 1-year low of $99.71 and a 1-year high of $121.64.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Wednesday, January 15th will be given a $0.59 dividend. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.55. This represents a $2.36 annualized dividend and a dividend yield of 2.13%. The ex-dividend date of this dividend is Wednesday, January 15th. Abbott Laboratories's dividend payout ratio (DPR) is currently 71.73%.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Oppenheimer began coverage on shares of Abbott Laboratories in a research note on Tuesday, October 8th. They set an "outperform" rating and a $130.00 target price for the company. Piper Sandler raised their price objective on Abbott Laboratories from $131.00 to $133.00 and gave the stock an "overweight" rating in a research report on Thursday, October 17th. Evercore ISI boosted their price target on shares of Abbott Laboratories to $136.00 and gave the company a "buy" rating in a report on Thursday, January 2nd. Jefferies Financial Group increased their price target on shares of Abbott Laboratories from $120.00 to $125.00 and gave the stock a "hold" rating in a research report on Thursday, October 17th. Finally, Piper Sandler Companies initiated coverage on Abbott Laboratories in a research note on Thursday, September 19th. They issued an "overweight" rating and a $131.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $131.57.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.